Joseph A. Sparano

TL;DR: In this article, the authors examined the feasibility of carbohydrate restricted diets in patients with advanced FDG-avid cancers and compared exit vs. baseline PET scan changes as surrogate measures for tumor response.

TL;DR: Patient reported side effect bother is needed to understand tolerability of cancer drugs, and increase in side effect bothers from baseline to cycle 7 as measured by E19136 is needed.

TL;DR: A genome wide approach for biomarker discovery with two validation cohorts to predict CHF from adult patients planning to receive an anthracycline, and 11 SNPs had a p-value <10-5 of which 9 independent chromosomal regions were associated with increased risk.

TL;DR: The maximum tolerated dose of IFN-alpha by the authors' criteria was 1 milliunit/m2, and neutropenia was the predominant toxic effect that precluded IFn-alpha dose escalation, and alternative CAF drug delivery schedules that are more amendable to hematopoietic growth factor support may be more suitable to combine with higher doses of IFNs that may produce modulation.